Balance Sheet Details (Tables)

9 Months Ended

Sep. 30, 2026

Balance Sheet Related Disclosures [Abstract]

Schedule of Accrued Expenses

Accrued expenses consist of the following (in thousands):


		September 30,				December 31,
		2026				2025
Accrued compensation expenses		$	14,389			$	14,841
Accrued professional & consulting expenses			1,414				1,253
Accrued research and development expenses			568				1,355
Accrued revenue allowances			98,151				65,462
Accrued other			6,625				6,920
Total accrued expenses		$	121,147			$	89,831

Schedule of Inventory

Inventory consists of the following (in thousands):


		September 30,				December 31,
		2026				2025
Finished goods		$	1,170			$	1,457
Raw materials			6,462				4,061
Total inventory, current			7,632				5,518
Raw materials, non-current			27,331				20,732
Total inventory		$	34,963			$	26,250

Raw materials consist of materials, including active pharmaceutical ingredients, to be consumed in the production of inventory related to FDA-approved products. Inventory that is used for clinical development purposes is expensed to research and development expense when consumed. Inventory, non-current includes inventory expected to remain on-hand beyond one year from the balance sheet dates presented.